Telavancin Treatment in the Outpatient Setting is Effective
October 21, 2011
BOSTON, MA (October 21, 2011) – In a 16 month period, 47 patients were treated with telavancin in 15 physician office infusion centers (POICs) with indications for acute bacterial skin and skin structure infections (24), osteomyelitis (19), sepsis (3), and pneumonia (1). MRSA was the most common infecting pathogen (53%), 25 days was the mean duration of therapy. The study reports treatment success with telavancin in 70% of skin and skin structure infections, 67% of osteomyelitis, 100% of sepsis and 100% of pneumonia. Co-morbidities in the patient population were common, with 55% having 3 or more, the most common being hypertension and diabetes. Adverse events occurred in 24 patients, the most common being gastrointestinal disorders (20%). Telavancin may be a useful treatment option for susceptible skin infections as well as osteomyelitis, sepsis, and pneumonia in the outpatient setting.
This study was presented at the 49th Annual Meeting of the Infectious Diseases Society of America. For a printed copy of this research poster study, please call 1.866.654.2451 or email email@example.com.
ABOUT HEALIX, INC.®
Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.
The 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) brings together physicians, scientists, and other health care professionals involved in research, patient care, public health, disease prevention, and education in the field of infectious diseases. The meeting showcases the latest news in the field of infectious diseases with emphasis on contemporary trends, including emerging infections, new diagnostic and therapeutic advances. IDSA 2011 takes place October 20-23 at the Boston Exhibition and Convention Center in Boston, Massachusetts. For more information, visit www.idsa2011.org.
Lucinda J. Van Anglen, PharmD